Posaconazole: The Case for Therapeutic Drug Monitoring

被引：31
|
作者：
Howard, Susan J. [1 ]
Felton, Timothy W. [1 ]
Gomez-Lopez, Alicia [2 ]
Hope, William W. [1 ]
机构：
[1] Univ Manchester, Sch Translat Med, Manchester Acad Hlth Sci Ctr, Manchester M13 9PT, Lancs, England
[2] Inst Salud Carlos III, Serv Micol, Ctr Nacl Microbiol, Majadahonda, Spain
来源：
THERAPEUTIC DRUG MONITORING | 2012年 / 34卷 / 01期
基金：
英国医学研究理事会;
关键词：
antifungal; posaconazole; triazole; therapeutic drug monitoring; pharmacokinetics; ORAL POSACONAZOLE; PHARMACOKINETICS; SAFETY; PHARMACODYNAMICS; ASPERGILLOSIS; TOLERABILITY; PROPHYLAXIS; EFFICACY; EXPOSURE;
D O I：
10.1097/FTD.0b013e31823cdeac
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
Invasive fungal infections are associated with high morbidity and mortality. Antifungal therapeutic options remain relatively limited; therefore, optimization of present regimens is essential. Posaconazole is licensed for prevention of invasive fungal infections and oropharyngeal candidiasis and salvage therapy for invasive aspergillosis. Recent data suggest that therapeutic drug monitoring may be an important tool for patient management. Clinical and laboratory animal data suggest that posaconazole demonstrates clinically relevant exposure-response relationships. Higher systemic drug exposure is associated with improved clinical outcomes. Potentially subtherapeutic concentrations are frequently encountered in critically ill patients. Therapeutic drug monitoring provides a way to optimize the use of posaconazole, and this review summarizes the indications and process by which this can be achieved.
引用
收藏
页码：72 / 76
页数：5
相关论文
共 50 条
  • [11] Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake
    Eiden, C.
    Meniane, J. C.
    Peyriere, H.
    Eymard-Duvernay, S.
    Le Falher, G.
    Ceballos, P.
    Fegueux, N.
    Cociglio, M.
    Reynes, J.
    Hillaire-Buys, D.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2012, 31 (02) : 161 - 167
  • [12] Posaconazole Treatment in Hematology Patients: A Pilot Study of Therapeutic Drug Monitoring
    Crombag, Marie-Rose B. S.
    Huisman, Cynthia
    Kemper, Elles M.
    Bruggemann, Roger J. M.
    Bijleveld, Yuma A.
    THERAPEUTIC DRUG MONITORING, 2012, 34 (03) : 320 - 325
  • [13] Refining the therapeutic range of posaconazole and isavuconazole for efficient therapeutic drug monitoring using a bioassay approach
    Willeman, Theo
    Tonini, Julia
    Garnaud, Cecile
    Bailly, Sebastien
    Gandia, Peggy
    Stanke-Labesque, Francoise
    Maubon, Daniele
    Gautier-Veyret, Elodie
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (02) : 279 - 287
  • [14] Therapeutic Drug Monitoring of Posaconazole in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
    Vaes, M.
    Hites, M.
    Cotton, F.
    Bourguignon, A. M.
    Csergo, M.
    Rasson, C.
    Ameye, L.
    Bron, D.
    Jacobs, F.
    Aoun, M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (12) : 6298 - 6303
  • [15] Making sense of posaconazole therapeutic drug monitoring: a practical approach
    Ananda-Rajah, Michelle R.
    Grigg, Andrew
    Slavin, Monica A.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (06) : 605 - 611
  • [16] Therapeutic drug monitoring of posaconazole delayed-release tablets and injections in pediatric patients
    Wu, Juan
    Chen, Changcheng
    Luo, Chengjuan
    Ning, Botao
    Liu, Yue
    Li, Zhuo
    Zhang, Shunguo
    Li, Zhiling
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (12)
  • [17] Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital
    Cabral-Galeano, Evelyn
    Ruiz-Camps, Isabel
    Len-Abad, Oscar
    Pou-Clave, Leonor
    Sorde-Masip, Roger
    Meije-Castillo, Yolanda
    Blanco-Grau, Albert
    Barba-Sunol, Pere
    Monforte-Torres, Victor
    Roman-Broto, Antonio
    Pahissa-Berga, Albert
    Gavalda-Santapau, Joan
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2015, 33 (05): : 298 - 302
  • [18] Using State Transition Models To Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension
    Lewis, Russell E.
    Kontoyiannis, Dimitrios P.
    Viale, Pierluigi
    Sarpong, Eric M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019, 63 (12)
  • [19] Alternative approaches to the therapeutic drug monitoring of prophylactic posaconazole in haematology patients
    Vyzantiadis, T. -A.
    Yannaki, E.
    Oliver, D. A.
    Markantonatou, A. -M.
    Boussiou, Z.
    Louka, A.
    Zachrou, E.
    Johnson, E. M.
    JOURNAL DE MYCOLOGIE MEDICALE, 2018, 28 (01): : 65 - 69
  • [20] Hypoalbuminemia and Posaconazole Therapeutic Drug Monitoring
    Nix, David E.
    Al-Obaidi, Mohanad
    Zangeneh, Tirdad
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (08):
12345